DCMM
FATE icon

DG Capital Management (Massachusetts)’s Fate Therapeutics FATE Stock Holding History

DG Capital Management (Massachusetts)’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-12,935
Closed -$82K – 67
2014
Q2 		$82K Buy
+12,935
New +$91.1K 0.05% 62

Other funds holding FATE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

DG Capital Management (Massachusetts)'s FATE Position: Q3 2014 in Review

DG Capital Management (Massachusetts) sold out of Fate Therapeutics (FATE) in Q3 2014, closing a stake of 12,935 shares — an estimated $82K sold.

DG Capital Management (Massachusetts) first reported a position in FATE in Q2 2014 and held it in 1 quarter. The position peaked at $82K in Q2 2014. 22 funds tracked by Wall St. Rank hold FATE as of Q3 2014.

  • DG Capital Management (Massachusetts) reported no remaining Fate Therapeutics position as of Q3 2014 after selling out during the quarter.
  • DG Capital Management (Massachusetts) sold 12,935 Fate Therapeutics shares in Q3 2014, an estimated $82K.
  • DG Capital Management (Massachusetts) first reported a position in Fate Therapeutics in Q2 2014 and held it in 1 quarter.
  • DG Capital Management (Massachusetts)'s Fate Therapeutics position peaked at $82K in Q2 2014.
  • 22 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2014.

Based on DG Capital Management (Massachusetts)'s 13F filing for Q3 2014, filed 12 Nov 2014.